A vertically integrated, plant-based ingredient and supplement company, Farlong Nutraceutical, is conducting a 90-day double blind, randomised, controlled, parallel study to determine the safety and effectiveness of Farlong Lifeflower® Breviscapine on improving long and short-term memory, concentration, and clarity of thinking in healthy individuals.
Farlong Lifeflower has long been used as a TCM product within the Chinese community, and Farlong Nutraceutical sources much of its raw material from its own farms in Yunnan Province in China.
The new clinical trial will use the company’s branded Lifeflower Breviscapine ingredient, an active flavonoid component extracted from Erigeron Breviscapus, containing more than 90% scutellarin. Scutellarin has been shown to enhance memory, cognitive function and brain health; increase brain circulation; and promote the development of new blood vessels.
The flowers of Erigeron breviscapus, has been used as a herb for centuries in Traditional Chinese Medicine (TCM), however it is relatively unknown in the West.
The clinical study will be led by clinician Melanie Montgomery, Ph.D., of LifeAlyze LLC. The partially grant-funded study comprises of 160 healthy individuals divided into 4 study groups, with the first given one placebo capsule daily, and the other 3 groups to receive different daily doses of Farlong Lifeflower® Breviscapine – 100 mg, 200 mg, and 400 mg each.
Jing Struve, CEO and Executive Director of Farlong Nutraceutical said, “We are very excited to be underway with this clinical study, as we take pride in providing consumers and practitioners with data, research and studies that showcase the effect of our products and the positive impact they can have in changing peoples’ lives.”
Farlong expects the study to be completed in November with results published soon thereafter.
